Skip to main content
14 week, Phase 4, Open Label, Decentralized Study finds that Viloxazine ER reduced ADHD symptoms by 45.3% in adults with comorbid depression/anxiety. 71.8% achieved ≥30% symptom reduction. Depression · ViralHub